Vytautas Petrauskas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vytautas Petrauskas has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Daumantas Matulis
Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center Vilnius University Vilnius Lithuania
21 shared publications - Lina Baranauskienė
Vilnius University Saulėtekio al. 7
10 shared publications E.E. Tornau
Semiconductor Physics Institute, Goštauto 11, LT-01108, Vilnius, Lithuania
6 shared publicationsZigmantas Toleikis
Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, 10257 Vilnius, Lithuania
6 shared publicationsDaumantas Matulis
Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, 10257 Vilnius, Lithuania
5 shared publications- Piotras Cimmperman
Baltic Institute of Advanced Technology, Vilnius, Lithuania
5 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22993-23008
Structure-Affinity and Selectivity of Aryl-Sulfamates as Inhibitors of Carbonic Anhydrase IX
Sulfamates inhibit carbonic anhydrases (CA), but are less investigated than sulfonamides, which comprise most CA inhibitors used as pharmaceuticals, except sulfamate topiramate, used clinically to treat epilepsy and migraine. To investigate structure−affinity relationships of sulfamates, we designed and synthesized a series of ortho- and meta-substituted sulfamates and determined their binding affinities by thermal shift assay, enzyme inhibition, and a live-cell competition assay targeting CA IX, an isozyme overexpressed in hypoxic solid tumors. The most promising compounds had Kd values of 0.5 nM. The X-ray crystal structures of sulfamates bound to CA isozymes revealed functional groups responsible for high affinity and selectivity. The pH-dependent affinity measurements revealed the mechanism of sulfamate binding to Zn(II) via the deprotonated, negatively charged amino group. Together with the stability against hydrolysis study, these findings provide insight into the molecular determinants of sulfamate binding and highlight opportunities and limitations of sulfamates for CA-targeted drug development.
- 29 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22993-23008
Open AccessStructure-Affinity and Selectivity of Aryl-Sulfamates as Inhibitors of Carbonic Anhydrase IX
Sulfamates inhibit carbonic anhydrases (CA), but are less investigated than sulfonamides, which comprise most CA inhibitors used as pharmaceuticals, except sulfamate topiramate, used clinically to treat epilepsy and migraine. To investigate structure−affinity relationships of sulfamates, we designed and synthesized a series of ortho- and meta-substituted sulfamates and determined their binding affinities by thermal shift assay, enzyme inhibition, and a live-cell competition assay targeting CA IX, an isozyme overexpressed in hypoxic solid tumors. The most promising compounds had Kd values of 0.5 nM. The X-ray crystal structures of sulfamates bound to CA isozymes revealed functional groups responsible for high affinity and selectivity. The pH-dependent affinity measurements revealed the mechanism of sulfamate binding to Zn(II) via the deprotonated, negatively charged amino group. Together with the stability against hydrolysis study, these findings provide insight into the molecular determinants of sulfamate binding and highlight opportunities and limitations of sulfamates for CA-targeted drug development.
- Open Access
- 10 June 2024
- Published by International Union of Crystallography (IUCr) in IUCrJ
- Vol. 11 (4) , 556-569
From X-ray crystallographic structure to intrinsic thermodynamics of protein–ligand binding using carbonic anhydrase isozymes as a model system
Carbonic anhydrase (CA) was among the first proteins whose X-ray crystal structure was solved to atomic resolution. CA proteins have essentially the same fold and similar active centers that differ in only several amino acids. Primary sulfonamides are well defined, strong and specific binders of CA. However, minor variations in chemical structure can significantly alter their binding properties. Over 1000 sulfonamides have been designed, synthesized and evaluated to understand the correlations between the structure and thermodynamics of their binding to the human CA isozyme family. Compound binding was determined by several binding assays: fluorescence-based thermal shift assay, stopped-flow enzyme activity inhibition assay, isothermal titration calorimetry and competition assay for enzyme expressed on cancer cell surfaces. All assays have advantages and limitations but are necessary for deeper characterization of these protein–ligand interactions. Here, the concept and importance of intrinsic binding thermodynamics is emphasized and the role of structure–thermodynamics correlations for the novel inhibitors of CA IX is discussed – an isozyme that is overexpressed in solid hypoxic tumors, and thus these inhibitors may serve as anticancer drugs. The abundant structural and thermodynamic data are assembled into the Protein–Ligand Binding Database to understand general protein–ligand recognition principles that could be used in drug discovery.
- 10 June 2024
- Published by International Union of Crystallography (IUCr) in IUCrJ
- Vol. 11 (4) , 556-569
Open AccessFrom X-ray crystallographic structure to intrinsic thermodynamics of protein–ligand binding using carbonic anhydrase isozymes as a model system
Carbonic anhydrase (CA) was among the first proteins whose X-ray crystal structure was solved to atomic resolution. CA proteins have essentially the same fold and similar active centers that differ in only several amino acids. Primary sulfonamides are well defined, strong and specific binders of CA. However, minor variations in chemical structure can significantly alter their binding properties. Over 1000 sulfonamides have been designed, synthesized and evaluated to understand the correlations between the structure and thermodynamics of their binding to the human CA isozyme family. Compound binding was determined by several binding assays: fluorescence-based thermal shift assay, stopped-flow enzyme activity inhibition assay, isothermal titration calorimetry and competition assay for enzyme expressed on cancer cell surfaces. All assays have advantages and limitations but are necessary for deeper characterization of these protein–ligand interactions. Here, the concept and importance of intrinsic binding thermodynamics is emphasized and the role of structure–thermodynamics correlations for the novel inhibitors of CA IX is discussed – an isozyme that is overexpressed in solid hypoxic tumors, and thus these inhibitors may serve as anticancer drugs. The abundant structural and thermodynamic data are assembled into the Protein–Ligand Binding Database to understand general protein–ligand recognition principles that could be used in drug discovery.
- 7 May 2024
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 19 (6) , 649-670
Recent advances in computational and experimental protein-ligand affinity determination techniques
Modern drug discovery revolves around designing ligands that target the chosen biomolecule, typically proteins. For this, the evaluation of affinities of putative ligands is crucial. This has given rise to a multitude of dedicated computational and experimental methods that are constantly being developed and improved. In this review, the authors reassess both the industry mainstays and the newest trends among the methods for protein - small-molecule affinity determination. They discuss both computational affinity predictions and experimental techniques, describing their basic principles, main limitations, and advantages. Together, this serves as initial guide to the currently most popular and cutting-edge ligand-binding assays employed in rational drug design. The affinity determination methods continue to develop toward miniaturization, high-throughput, and in-cell application. Moreover, the availability of data analysis tools has been constantly increasing. Nevertheless, cross-verification of data using at least two different techniques and careful result interpretation remain of utmost importance.
- 7 May 2024
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 19 (6) , 649-670
Recent advances in computational and experimental protein-ligand affinity determination techniques
Modern drug discovery revolves around designing ligands that target the chosen biomolecule, typically proteins. For this, the evaluation of affinities of putative ligands is crucial. This has given rise to a multitude of dedicated computational and experimental methods that are constantly being developed and improved. In this review, the authors reassess both the industry mainstays and the newest trends among the methods for protein - small-molecule affinity determination. They discuss both computational affinity predictions and experimental techniques, describing their basic principles, main limitations, and advantages. Together, this serves as initial guide to the currently most popular and cutting-edge ligand-binding assays employed in rational drug design. The affinity determination methods continue to develop toward miniaturization, high-throughput, and in-cell application. Moreover, the availability of data analysis tools has been constantly increasing. Nevertheless, cross-verification of data using at least two different techniques and careful result interpretation remain of utmost importance.
- Open Access
- 13 November 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (47) , 44571-44577
Intrinsic Solubility of Ionizable Compounds from pKa Shift
Aqueous solubility of pharmaceutical substances plays an important role in small molecule drug discovery and development, with ionizable groups often employed to enhance solubility. Drug candidate compounds often contain ionizable groups to increase their solubility. Recognizing that the electrostatically charged form of the compound is much more soluble than the uncharged form, this work proposes a model to explore the relationship between the pKa shift of the ionizable group and dissolution equilibria. The model considers three forms of a compound: dissolved-charged, dissolved-uncharged, and aggregated-uncharged. It analyzes two linked equilibria: the protonation of the ionizable group and the dissolution-aggregation of the uncharged form, with the observed pKa shift depending on the total concentration of the compound. The active concentration of the aggregates determines this shift. The model was explored through the determination of the pKa shift and intrinsic solubility of specific compounds, such as ICPD47, a high-affinity inhibitor of the Hsp90 chaperone protein and anticancer target, as well as benzoic acid and benzydamine. The model holds the potential for a more nuanced understanding of intrinsic solubility and may lead to advancements in drug discovery and development.
- 13 November 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (47) , 44571-44577
Open AccessIntrinsic Solubility of Ionizable Compounds from pKa Shift
Aqueous solubility of pharmaceutical substances plays an important role in small molecule drug discovery and development, with ionizable groups often employed to enhance solubility. Drug candidate compounds often contain ionizable groups to increase their solubility. Recognizing that the electrostatically charged form of the compound is much more soluble than the uncharged form, this work proposes a model to explore the relationship between the pKa shift of the ionizable group and dissolution equilibria. The model considers three forms of a compound: dissolved-charged, dissolved-uncharged, and aggregated-uncharged. It analyzes two linked equilibria: the protonation of the ionizable group and the dissolution-aggregation of the uncharged form, with the observed pKa shift depending on the total concentration of the compound. The active concentration of the aggregates determines this shift. The model was explored through the determination of the pKa shift and intrinsic solubility of specific compounds, such as ICPD47, a high-affinity inhibitor of the Hsp90 chaperone protein and anticancer target, as well as benzoic acid and benzydamine. The model holds the potential for a more nuanced understanding of intrinsic solubility and may lead to advancements in drug discovery and development.
- 24 June 2022
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 24 (28) , 17279-17288
Denaturant- or ligand-induced changes in protein volume by pressure shift assay
Protein–ligand binding volumes were determined in the FPSA experiment by varying both the ligand and GdmHCl concentrations. GdmHCl-induced unfolding pathways of carbonic anhydrase isoforms II and XIII differ from isoform I.
- 24 June 2022
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 24 (28) , 17279-17288
Denaturant- or ligand-induced changes in protein volume by pressure shift assay
Protein–ligand binding volumes were determined in the FPSA experiment by varying both the ligand and GdmHCl concentrations. GdmHCl-induced unfolding pathways of carbonic anhydrase isoforms II and XIII differ from isoform I.
- Open Access
- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6781
Interactions between S100A9 and Alpha-Synuclein: Insight from NMR Spectroscopy
S100A9 is a pro-inflammatory protein that co-aggregates with other proteins in amyloid fibril plaques. S100A9 can influence the aggregation kinetics and amyloid fibril structure of alpha-synuclein (-syn), which is involved in Parkinson’s disease. Currently, there are limited data regarding their cross-interaction and how it influences the aggregation process. In this work, we analyzed this interaction using solution F and 2D 15N–1H HSQC NMR spectroscopy and studied the aggregation properties of these two proteins. Here, we show that -syn interacts with S100A9 at specific regions, which are also essential in the first step of aggregation. We also demonstrate that the 4-fluorophenylalanine label in alpha-synuclein is a sensitive probe to study interaction and aggregation using F NMR spectroscopy.- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6781
Open AccessInteractions between S100A9 and Alpha-Synuclein: Insight from NMR Spectroscopy
S100A9 is a pro-inflammatory protein that co-aggregates with other proteins in amyloid fibril plaques. S100A9 can influence the aggregation kinetics and amyloid fibril structure of alpha-synuclein (-syn), which is involved in Parkinson’s disease. Currently, there are limited data regarding their cross-interaction and how it influences the aggregation process. In this work, we analyzed this interaction using solution F and 2D 15N–1H HSQC NMR spectroscopy and studied the aggregation properties of these two proteins. Here, we show that -syn interacts with S100A9 at specific regions, which are also essential in the first step of aggregation. We also demonstrate that the 4-fluorophenylalanine label in alpha-synuclein is a sensitive probe to study interaction and aggregation using F NMR spectroscopy. - 13 May 2022
- Published by Elsevier in Drug Discovery Today
- Vol. 27 (8) , 2076-2079
Thermott: A comprehensive online tool for protein–ligand binding constant determination
- 13 May 2022
- Published by Elsevier in Drug Discovery Today
- Vol. 27 (8) , 2076-2079
Thermott: A comprehensive online tool for protein–ligand binding constant determination
- Open Access
- 26 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (15) , 7972
S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation
The formation of amyloid fibril plaques in the brain creates inflammation and neuron death. This process is observed in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Alpha-synuclein is the main protein found in neuronal inclusions of patients who have suffered from Parkinson’s disease. S100A9 is a calcium-binding, pro-inflammation protein, which is also found in such amyloid plaques. To understand the influence of S100A9 on the aggregation of -synuclein, we analyzed their co-aggregation kinetics and the resulting amyloid fibril structure by Fourier-transform infrared spectroscopy and atomic force microscopy. We found that the presence of S100A9 alters the aggregation kinetics of -synuclein and stabilizes the formation of a particular amyloid fibril structure. We also show that the solution’s ionic strength influences the interplay between S100A9 and -synuclein, stabilizing a different structure of -synuclein fibrils.- 26 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (15) , 7972
Open AccessS100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation
The formation of amyloid fibril plaques in the brain creates inflammation and neuron death. This process is observed in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Alpha-synuclein is the main protein found in neuronal inclusions of patients who have suffered from Parkinson’s disease. S100A9 is a calcium-binding, pro-inflammation protein, which is also found in such amyloid plaques. To understand the influence of S100A9 on the aggregation of -synuclein, we analyzed their co-aggregation kinetics and the resulting amyloid fibril structure by Fourier-transform infrared spectroscopy and atomic force microscopy. We found that the presence of S100A9 alters the aggregation kinetics of -synuclein and stabilizes the formation of a particular amyloid fibril structure. We also show that the solution’s ionic strength influences the interplay between S100A9 and -synuclein, stabilizing a different structure of -synuclein fibrils. - Open Access
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0253608
Thiazide and other Cl-benzenesulfonamide-bearing clinical drug affinities for human carbonic anhydrases
Twelve carbonic anhydrase (CA) isoforms catalyze carbon dioxide hydration to bicarbonate and acid protons and are responsible for many biological functions in human body. Despite their vital functions, they are also responsible for, or implicated in, numerous ailments and diseases such as glaucoma, high altitude sickness, and cancer. Because CA isoforms are highly homologous, clinical drugs designed to inhibit enzymatic activity of a particular isoform, can also bind to others with similar affinity causing toxic side effects. In this study, the affinities of twelve CA isoforms have been determined for nineteen clinically used drugs used to treat hypertension related diseases, i.e. thiazides, indapamide, and metolazone. Their affinities were determined using a fluorescent thermal shift assay. Stopped flow assay and isothermal titration calorimetry were also employed on a subset of compounds and proteins to confirm inhibition of CA enzymatic activity and verify the quantitative agreement between different assays. The findings of this study showed that pharmaceuticals could bind to human CA isoforms with variable affinities and inhibit their catalytic activity, even though the drug was intended to interact with a different (non-CA) protein target. Relatively minor structural changes of the compounds may cause significant changes in affinity and selectivity for a particular CA isoform.
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0253608
Open AccessThiazide and other Cl-benzenesulfonamide-bearing clinical drug affinities for human carbonic anhydrases
Twelve carbonic anhydrase (CA) isoforms catalyze carbon dioxide hydration to bicarbonate and acid protons and are responsible for many biological functions in human body. Despite their vital functions, they are also responsible for, or implicated in, numerous ailments and diseases such as glaucoma, high altitude sickness, and cancer. Because CA isoforms are highly homologous, clinical drugs designed to inhibit enzymatic activity of a particular isoform, can also bind to others with similar affinity causing toxic side effects. In this study, the affinities of twelve CA isoforms have been determined for nineteen clinically used drugs used to treat hypertension related diseases, i.e. thiazides, indapamide, and metolazone. Their affinities were determined using a fluorescent thermal shift assay. Stopped flow assay and isothermal titration calorimetry were also employed on a subset of compounds and proteins to confirm inhibition of CA enzymatic activity and verify the quantitative agreement between different assays. The findings of this study showed that pharmaceuticals could bind to human CA isoforms with variable affinities and inhibit their catalytic activity, even though the drug was intended to interact with a different (non-CA) protein target. Relatively minor structural changes of the compounds may cause significant changes in affinity and selectivity for a particular CA isoform.